Kaplan & Sadock's Synopsis of Psychiatry - 12th Edition
(Boland, 2025) | Complete Test Bank | All Chapters 1-35 with
Verified Answer - 200 Questions and Answers Already Graded
A+ Premium Exam Tested And Verified
Subject Area Psychiatry
Description This exam assesses advanced understanding of psychiatric diagnosis,
neurobiology, psychopharmacology, and therapeutic interventions as detailed in
Kaplan & Sadock's Synopsis of Psychiatry, 12th Edition (2025). Questions are
designed to test synthesis of concepts across chapters, requiring integration of
basic neuroscience, clinical reasoning, and evidence-based practice.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Integrate neurobiological underpinnings with clinical presentation and
treatment selection.
2. Critically evaluate psychopharmacological mechanisms and their clinical
implications.
3. Apply DSM-5-TR criteria to complex and atypical presentations.
4. Analyze ethical and legal issues in psychiatric practice.
5. Synthesize data from multiple sources to formulate comprehensive treatment
plans.
Accreditation This examination meets the standards of US medical school psychiatry clerkships
and graduate-level psychopharmacology courses accredited by the Liaison
Committee on Medical Education (LCME).
Page 1
,1. A patient with treatment-resistant depression has a history of nonresponse to
SSRIs, SNRIs, and bupropion. Which augmentation strategy is most likely to be
effective based on recent evidence from the STAR*D trial?
A. Addition of aripiprazole to the current SSRI
B. Switch to a monoamine oxidase inhibitor
C. Augmentation with lithium or thyroid hormone
D. Addition of buspirone to the current regimen
Answer: C. Augmentation with lithium or thyroid hormone
The STAR*D trial demonstrated that augmentation with lithium or thyroid hormone
(T3) was effective for patients who did not respond to multiple antidepressant trials.
Aripiprazole augmentation is also effective but was not part of STAR*D's main
augmentation arms. MAOIs are reserved for atypical depression, and buspirone
augmentation showed modest benefit.
2. Which neurobiological mechanism best explains the efficacy of clozapine in
treatment-resistant schizophrenia, despite its lack of D2 receptor occupancy typical
of other antipsychotics?
A. High affinity for D4 receptors
B. Selective antagonism of 5-HT2A receptors
C. Rapid dissociation from D2 receptors
D. Agonism at mGluR2/3 receptors
Answer: C. Rapid dissociation from D2 receptors
Clozapine's rapid dissociation from D2 receptors (low affinity, high Koff rate) allows
for transient dopamine blockade, reducing extrapyramidal symptoms while still
achieving antipsychotic effect. This property, rather than D4 or 5-HT2A selectivity, is
key to its unique profile. mGluR2/3 agonism is not a clozapine mechanism.
Page 2
,3. A patient presents with recurrent, intrusive thoughts of contamination and
compulsive hand washing. Despite insight that the behaviors are excessive, the
patient spends hours daily performing rituals. Which cognitive-behavioral concept
most directly explains the maintenance of this cycle?
A. Negative reinforcement through anxiety reduction
B. Positive reinforcement from relief of obsessions
C. Classical conditioning of fear to neutral stimuli
D. Operant conditioning via social attention
Answer: A. Negative reinforcement through anxiety reduction
Compulsive behaviors are negatively reinforced because they temporarily reduce the
anxiety associated with obsessions. This reduction strengthens the compulsion,
perpetuating the cycle. Positive reinforcement (e.g., relief) is not the primary
mechanism; relief is a consequence, not a reinforcer. Classical conditioning explains
acquisition, not maintenance.
4. In a double-blind placebo-controlled trial, a new drug shows a statistically
significant reduction in depressive symptoms (p=0.04) but a Cohen's d of 0.15.
Which interpretation is most appropriate?
A. The drug is clinically meaningful due to statistical significance
B. The effect size is small, limiting clinical significance
C. The p-value indicates a 4% chance of no effect
D. The drug is no better than placebo due to small effect size
Answer: B. The effect size is small, limiting clinical significance
Cohen's d = 0.15 indicates a small effect size, meaning the drug's benefit over placebo is
minimal, even if statistically significant. Statistical significance does not equate to
clinical significance. Option C misinterprets p-value. Option D ignores statistical
significance; the drug is better but not meaningfully so.
Page 3
, 5. Which of the following best explains the high comorbidity between posttraumatic
stress disorder (PTSD) and substance use disorders?
A. Shared genetic vulnerability to both conditions
B. Self-medication hypothesis: substances reduce intrusive symptoms
C. Kindling effect: substance use sensitizes fear circuitry
D. Both B and C are supported by evidence
Answer: D. Both B and C are supported by evidence
The self-medication hypothesis (substances temporarily alleviate PTSD symptoms) and
the kindling effect (substances exacerbate fear conditioning) are both supported.
Shared genetic factors exist but are less explanatory for the temporal relationship. The
combination of negative reinforcement and neurobiological sensitization is key.
6. A patient with bipolar I disorder is stabilized on lithium. Routine labs show:
lithium level 0.8 mEq/L, TSH 6.5 mIU/L (normal 0.4-4.0), free T4 0.7 ng/dL (normal
0.8-1.8). Which intervention is most appropriate?
A. Discontinue lithium and start valproate
B. Add levothyroxine while continuing lithium
C. Increase lithium dose to achieve level 1.0 mEq/L
D. Start amiodarone for thyroid suppression
Answer: B. Add levothyroxine while continuing lithium
Lithium commonly causes hypothyroidism (elevated TSH, low free T4). The standard
approach is to continue lithium (if mood-stabilizing) and add levothyroxine
replacement. Discontinuing lithium risks mood relapse. Amiodarone is not indicated.
Increasing lithium dose could worsen thyroid function.
Page 4
(Boland, 2025) | Complete Test Bank | All Chapters 1-35 with
Verified Answer - 200 Questions and Answers Already Graded
A+ Premium Exam Tested And Verified
Subject Area Psychiatry
Description This exam assesses advanced understanding of psychiatric diagnosis,
neurobiology, psychopharmacology, and therapeutic interventions as detailed in
Kaplan & Sadock's Synopsis of Psychiatry, 12th Edition (2025). Questions are
designed to test synthesis of concepts across chapters, requiring integration of
basic neuroscience, clinical reasoning, and evidence-based practice.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Integrate neurobiological underpinnings with clinical presentation and
treatment selection.
2. Critically evaluate psychopharmacological mechanisms and their clinical
implications.
3. Apply DSM-5-TR criteria to complex and atypical presentations.
4. Analyze ethical and legal issues in psychiatric practice.
5. Synthesize data from multiple sources to formulate comprehensive treatment
plans.
Accreditation This examination meets the standards of US medical school psychiatry clerkships
and graduate-level psychopharmacology courses accredited by the Liaison
Committee on Medical Education (LCME).
Page 1
,1. A patient with treatment-resistant depression has a history of nonresponse to
SSRIs, SNRIs, and bupropion. Which augmentation strategy is most likely to be
effective based on recent evidence from the STAR*D trial?
A. Addition of aripiprazole to the current SSRI
B. Switch to a monoamine oxidase inhibitor
C. Augmentation with lithium or thyroid hormone
D. Addition of buspirone to the current regimen
Answer: C. Augmentation with lithium or thyroid hormone
The STAR*D trial demonstrated that augmentation with lithium or thyroid hormone
(T3) was effective for patients who did not respond to multiple antidepressant trials.
Aripiprazole augmentation is also effective but was not part of STAR*D's main
augmentation arms. MAOIs are reserved for atypical depression, and buspirone
augmentation showed modest benefit.
2. Which neurobiological mechanism best explains the efficacy of clozapine in
treatment-resistant schizophrenia, despite its lack of D2 receptor occupancy typical
of other antipsychotics?
A. High affinity for D4 receptors
B. Selective antagonism of 5-HT2A receptors
C. Rapid dissociation from D2 receptors
D. Agonism at mGluR2/3 receptors
Answer: C. Rapid dissociation from D2 receptors
Clozapine's rapid dissociation from D2 receptors (low affinity, high Koff rate) allows
for transient dopamine blockade, reducing extrapyramidal symptoms while still
achieving antipsychotic effect. This property, rather than D4 or 5-HT2A selectivity, is
key to its unique profile. mGluR2/3 agonism is not a clozapine mechanism.
Page 2
,3. A patient presents with recurrent, intrusive thoughts of contamination and
compulsive hand washing. Despite insight that the behaviors are excessive, the
patient spends hours daily performing rituals. Which cognitive-behavioral concept
most directly explains the maintenance of this cycle?
A. Negative reinforcement through anxiety reduction
B. Positive reinforcement from relief of obsessions
C. Classical conditioning of fear to neutral stimuli
D. Operant conditioning via social attention
Answer: A. Negative reinforcement through anxiety reduction
Compulsive behaviors are negatively reinforced because they temporarily reduce the
anxiety associated with obsessions. This reduction strengthens the compulsion,
perpetuating the cycle. Positive reinforcement (e.g., relief) is not the primary
mechanism; relief is a consequence, not a reinforcer. Classical conditioning explains
acquisition, not maintenance.
4. In a double-blind placebo-controlled trial, a new drug shows a statistically
significant reduction in depressive symptoms (p=0.04) but a Cohen's d of 0.15.
Which interpretation is most appropriate?
A. The drug is clinically meaningful due to statistical significance
B. The effect size is small, limiting clinical significance
C. The p-value indicates a 4% chance of no effect
D. The drug is no better than placebo due to small effect size
Answer: B. The effect size is small, limiting clinical significance
Cohen's d = 0.15 indicates a small effect size, meaning the drug's benefit over placebo is
minimal, even if statistically significant. Statistical significance does not equate to
clinical significance. Option C misinterprets p-value. Option D ignores statistical
significance; the drug is better but not meaningfully so.
Page 3
, 5. Which of the following best explains the high comorbidity between posttraumatic
stress disorder (PTSD) and substance use disorders?
A. Shared genetic vulnerability to both conditions
B. Self-medication hypothesis: substances reduce intrusive symptoms
C. Kindling effect: substance use sensitizes fear circuitry
D. Both B and C are supported by evidence
Answer: D. Both B and C are supported by evidence
The self-medication hypothesis (substances temporarily alleviate PTSD symptoms) and
the kindling effect (substances exacerbate fear conditioning) are both supported.
Shared genetic factors exist but are less explanatory for the temporal relationship. The
combination of negative reinforcement and neurobiological sensitization is key.
6. A patient with bipolar I disorder is stabilized on lithium. Routine labs show:
lithium level 0.8 mEq/L, TSH 6.5 mIU/L (normal 0.4-4.0), free T4 0.7 ng/dL (normal
0.8-1.8). Which intervention is most appropriate?
A. Discontinue lithium and start valproate
B. Add levothyroxine while continuing lithium
C. Increase lithium dose to achieve level 1.0 mEq/L
D. Start amiodarone for thyroid suppression
Answer: B. Add levothyroxine while continuing lithium
Lithium commonly causes hypothyroidism (elevated TSH, low free T4). The standard
approach is to continue lithium (if mood-stabilizing) and add levothyroxine
replacement. Discontinuing lithium risks mood relapse. Amiodarone is not indicated.
Increasing lithium dose could worsen thyroid function.
Page 4
